---
title: What FDA CRLs Reveal - White Paper Series
description: Lessons from recent Complete Response Letters published by the FDA
image: https://info.solvias.com/hubfs/LSC.png
---

[![Logo_2024](https://info.solvias.com/hubfs/identity/logos/Logo_2024.svg "Logo_2024")](https://www.solvias.com/)

[![solvias_logo_2024_color](https://info.solvias.com/hs-fs/hubfs/solvias_logo_2024_color.jpg?width=1550&height=540&name=solvias_logo_2024_color.jpg "solvias_logo_2024_color")](https://info.solvias.com/https://www.solvias.com/?hsLang=en)

[![solvias_logo_2024_color](https://info.solvias.com/hs-fs/hubfs/solvias_logo_2024_color.jpg?width=1550&height=540&name=solvias_logo_2024_color.jpg "solvias_logo_2024_color")](https://www.solvias.com/)

- [Expertise](https://www.solvias.com/expertise/)
- [Services](https://www.solvias.com/services/)
- [Products](https://www.solvias.com/products/)
- [Quality & Regulatory](https://www.solvias.com/quality-regulatory/)
- [About Us](https://www.solvias.com/about-us/)
- [Resources](https://www.solvias.com/resources/)

More results

[CONNECT WITH US](https://www.solvias.com/about-us/contact-us/)

[Buy Now](https://www.hubspot.com/)

[CONNECT WITH US](https://www.solvias.com/about-us/contact-us/)

[Buy Now](https://www.hubspot.com/)

Lessons from recent Complete Response Letters published by the FDA

# What FDA CRLs Reveal

White Paper Series

Since the FDA began publishing Complete Response Letters (CRLs), we’ve been analyzing them to uncover where drug applications fall short and how to avoid the same pitfalls. The result is a growing library of white papers translating real regulatory feedback into actionable insights. 

So far, we have launched four white papers, each addressing critical areas of regulatory scrutiny: Extractables and Leachables (E&L), Container Closure Integrity Testing (CCIT), Method Validation and Cell-based Assays (CBBA).

Fill out the form below to unlock the series and access practical recommendations grounded in real FDA feedback. 

![Untitled design (18)-1](https://info.solvias.com/hubfs/Untitled%20design%20(18)-1.png "Untitled design (18)-1")

# What you will learn

![Untitled-2](https://info.solvias.com/hs-fs/hubfs/Untitled-2.png?width=100&height=101&name=Untitled-2.png)

### **FDA CRL Insights**

Discover the most common deficiencies cited in recent FDA Complete Response Letters

![Untitled-2](https://info.solvias.com/hs-fs/hubfs/Untitled-2.png?width=100&height=101&name=Untitled-2.png)

### Proactive Strategies

 Learn practical strategies to avoid the same mistakes and strengthen regulatory submissions

![Untitled-2](https://info.solvias.com/hs-fs/hubfs/Untitled-2.png?width=100&height=101&name=Untitled-2.png)

### Specific Insights

Learn how E&L, CCIT, and method validation issues are interpreted by regulators

![solvias_logo_2024_color](https://info.solvias.com/hs-fs/hubfs/solvias_logo_2024_color.jpg?width=1550&height=540&name=solvias_logo_2024_color.jpg)

 

[info@solvias.com](mailto:info@solvias.com)

<https://www.linkedin.com/company/solvias-ag/>[Join us on Slack](https://www.youtube.com/@SolviasAG)

- [Expertise](https://www.solvias.com/expertise/)
- [Services](https://www.solvias.com/services/)
- [Products](https://www.solvias.com/products/)
- [Quality & Regulatory](https://www.solvias.com/quality-regulatory/)
- [About Us](https://www.solvias.com/about-us/)
- [Resources](https://www.solvias.com/resources/)

 Copyright © 2026 Solvias.

- [Privacy Policy](https://www.solvias.com/privacy-policy/)
- [Accessibility Statement](https://www.solvias.com/accessibility-statement/)